NCT01730885已完成4 期
A Trial Investigating the Accuracy and Precision of the BGStar® and iBGStar® Blood Glucose Meter in Subjects With Type 1 Diabetes
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal
研究概览
简要总结
Due to continuing technological progress and better understanding of the needs for glucose monitoring, the performance requirements of blood glucose meters, primarily regarding their accuracy, are constantly debated and keep evolving as a consequence. Recently a discussion was initiated by the Food and Drug Administration (FDA) to improve the accuracy of BG meters in the point-of-care testing setting by asking for fulfilment of higher requirements.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
- •Male or female subjects aged 18-74 years (both inclusive).
- •Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months.
- •Body mass index 18.0-28.0 kg/m2 (both inclusive).
- •HbA1c ≤ 9.0 % by local laboratory analysis.
排除标准
- •Known or suspected hypersensitivity to lancet fingerpricks / needle injections.
- •Previous participation in this trial. Participation is defined as having performed at least one BG meter measurement as part of the study.
- •Receipt of any investigational medicinal product within 30 days before randomisation in this trial.
- •Formation of callus on the fingertips or any other skin condition that may hamper fingerprick blood sampling and/or insufficient capillary blood volume sampling (< 50 μL) during test fingerprick(s).
- •Haemoglobin < 8.0 mmol/L (male) or < 6.4 mmol/L (female), total leukocyte count < 3.0 x 109/L, thrombocytes <100 x 109/L, serum creatinine levels ≥ 126 μmol/L (male) or ≥ 111 μmol/L (female), bilirubin > 3x the upper limit of normal (ULN), and alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamyl transferase (γ-GT) > 2 x ULN.
- •Suffer from or history of a life threatening disease (i.e. cancer except basal cell skin cancer or squamous cell skin cancer), or any clinically significant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (with the exception of diabetes mellitus and euthyroid struma), haematological, dermatological, venereal, -
结局指标
主要结局
Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal
时间窗: 6 hours
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
撤回
不适用
Continuous Glucose Monitoring in InpatientsHyperglycemiaNCT06329297Parkview Health80
已完成
不适用
New Generation Enlite Accuracy StudyDiabetesNCT02423798Medtronic Diabetes24
已完成
不适用
Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring SystemsDiabetes MellitusNCT01751932Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)24
已完成
不适用
Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With DiabetesDiabetesNCT00805506HealthPartners Institute16
撤回
不适用
Introducing CGM at Type 1 Diabetes DiagnosisType1diabetesHypoglycemiaNCT03736083University of Florida